Estrogen, Total and Fractionated
Estrogens consist of a group of hormones primarily involved in the female reproductive physiologic functions. Biologically active estrogens include Estrone (E1), Estradiol (E2) and Estriol (E3). Estradiol (E2) is biologically more potent than Estrone (E1) and is primarily produced by ovaries in females and testes in males via aromatization of testosterone. To a lesser extent, adrenal glands and adipose tissue aromatize androstenedione and contribute to circulating E2 in both the sexes. In contrast, E1 is primarily produced by adipose tissue via aromatization of androstenedione. Estriol (E3) is primarily produced by the placenta and hence its levels are significantly higher during pregnancy.
While E1 levels remain somewhat unchanged throughout the life of a female, the levels of E2 are much diminished in pre-pubertal females, significantly high in females of reproductive age group, and decrease after menopause. The levels of estradiol (E2) fluctuate during menstrual cycle, being lowest in the follicular phase and peaking just before ovulation. The levels of E2 increase during the pubertal stages of development in both the sexes. Tanner staging categorizes this development into five stages with Tanner stage I being prepubertal stage and Tanner stage V corresponding to adulthood. Reference values for serum estradiol (E2) needs to be adjusted to the Tanner stage of development (please see reference values section).
Estrogen is secreted into the bloodstream where most of it (98%) is bound to sex hormone-binding globulin. The unbound free estrogen (2% of total) is the biologically active form. It primarily affects female reproductive organs. The non-reproductive functions of estrogen are many and include collagen metabolism in skin and connective tissue, mineralization of bone, lipid metabolism, regulation of coagulation and platelet adhesion, and cognitive functions of central nervous system.
Evaluation of serum estradiol (using moderately sensitive assays) serves as an important indicator of female reproductive functions and helps clinical assessment of oligomenorrhea, menopause, infertility and assisted reproductive techniques. Other clinical applications are possible, particularly when highly sensitive assays are employed and they include, but are not limited to, diagnosis of inborn errors of sex steroid metabolism, developmental disorders involving the reproductive system (in both males and females), feminizing disorders of males, therapeutic drug monitoring of estrogen receptor antagonists and estrogen secreting tumors (mostly in males, but also in females).
- Evaluation of hypogonadism – congenital (Turner’s syndrome, premature ovarian failure) and acquired (autoimmune, trauma, chemotherapy induced, radiation induced)
- Evaluation of menstrual irregularities – amenorrhea, polycystic ovarian syndrome, ovarian neoplasms, etc.
- Evaluation of osteoporosis and hormone replacement therapy in postmenopausal women
- Therapeutic drug monitoring of selective estrogen receptor modifiers (SERM)
- Evaluation of gynecomastia and other feminizing disorders in men – obesity, liver disease and estrogen secreting tumors
- Evaluation of disorders of puberty – precocious puberty and delayed puberty
- Evaluation of menstrual cycle in assisted reproductive procedures including inducing ovulation
| Adults (pg/mL) | |
| Group | Reference Range (pg/mL) |
| Males | 10–40 |
| Females (reproductive age) | 15–350 |
| Females (post-menopausal) | <10 |
Children:
- Neonates: Serum estradiol levels are greatly elevated at birth and fall to baseline prepubertal levels at 3-4 weeks of life.
- Serum estradiol levels at puberty (for both males and females) vary with the Tanner stage of development and are summarized in the table below:
| Tanner Stage (Males) | Mean Age (Years) | Reference Range (pg/mL) |
| Stage I (>14 days to prepuberty) | 7.1 | Undetectable to 13 |
| Stage II | 12.1 | Undetectable to 16 |
| Stage III | 13.6 | Undetectable to 26 |
| Stage IV | 15.1 | Undetectable to 38 |
| Stage V | 18 | 10–40 |
| Tanner Stage (Females) | Mean Age (Years) | Reference Range (pg/mL) |
| Stage I (>14 days to prepuberty) | 7.1 | Undetectable to 20 |
| Stage II | 10.5 | Undetectable to 24 |
| Stage III | 11.6 | Undetectable to 60 |
| Stage IV | 12.3 | 15–85 |
| Stage V | 14.5 | 15–350* |
Serum (SST) or Plasma EDTA.
Stability
- Ambient: 3-5 days
- Refrigeration: 5-7 days
- Frozen: 60 days
- J Midwifery Womens Health. 2002 May-Jun;47(3):130-8. [PMID: 12071379]
- Pediatr Res. 1973 Nov;7(11):901-7. [PMID: 4795966]
- Clin Chem Lab Med. 2002 Nov;40(11):1151-60. [PMID: 12521235]
- Ann Clin Biochem. 1988 Sep;25 ( Pt 5):466-83. [PMID: 3069043]
- Ann Clin Biochem. 2009 Nov;46(Pt 6):441-56. [PMID: 19841104]
- Speroff L, Glass RH, Kase NG (editors). Clinical gynecologic endocrinology and infertility. 4th ed. Baltimore:Williams and Wilkins (1989). pp. 91–119.